The preliminary results of a phase 2 study in 137 patients with CD79A/CD79B-mutant TN and R/R DLBCL found the addition of zanubrutinib to augment R-CHOP or salvage therapy (87). Here, CD79B is linked to diffuse large B-cell lymphoma.